TH17 cells in tumour immunity and immunotherapy

Nature Reviews Immunology

Volumn 10, Issue 4, 2010, Pages 248-256

  Zou, Weiping ^a   Restifo, Nicholas P ^b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE;

ANTINEOPLASTIC ACTIVITY; AUTOIMMUNE DISEASE; CANCER IMMUNOTHERAPY; CELL DIFFERENTIATION; CELL INTERACTION; EFFECTOR CELL; HUMAN; IMMUNOTHERAPY; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE ACTIVATION; TH17 CELL; TUMOR IMMUNITY;

ANIMALS; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-17; NEOPLASMS; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, HELPER-INDUCER;

EID: 77950196277     PISSN: 14741733     EISSN: None     Source Type: Journal    
DOI: 10.1038/nri2742     Document Type: Review

References (107)

1. Weaver, C. T., Harrington, L. E., Mangan, P. R., Gavrieli, M. & Murphy, K. M. Th17: an effector CD4 T cell lineage with regulatory T cell ties. Immunity 24, 677-688 (2006).
2. Dong, C. Diversification of T-helper-cell lineages: finding the family root of IL-17-producing cells. Nature Rev. Immunol. 6, 329-333 (2006).
3. H2. Nature Immunol. 6, 1069-1070 (2005).
4. + effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nature Immunol. 6, 1123-1132 (2005).
5. Sutton, C., Brereton, C., Keogh, B., Mills, K. H. & Lavelle, E. C. A crucial role for interleukin (IL)-1 in the induction of IL-17-producing T cells that mediate autoimmune encephalomyelitis. J. Exp. Med. 203, 1685-1691 (2006).
6. Komiyama, Y. et al. IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis. J. Immunol. 177, 566-573 (2006).
7. Tato, C. M. & O'Shea, J. J. Immunology: what does it mean to be just 17? Nature 441, 166-168 (2006).
8. Ouyang, W., Kolls, J. K. & Zheng, Y. The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity 28, 454-467 (2008).
9. Kolls, J. K. & Linden, A. Interleukin-17 family members and inflammation. Immunity 21, 467-476 (2004).
10. Reg cell lineages: a (co-)evolutionary perspective. Nature Rev. Immunol. 9, 883-889 (2009).
11. Dubin, P. J. & Kolls, J. K. Th17 cytokines and mucosal immunity. Immunol. Rev. 226, 160-171 (2008).
12. O'Quinn, D. B., Palmer, M. T., Lee, Y. K. & Weaver, C. T. Emergence of the Th17 pathway and its role in host defense. Adv. Immunol. 99, 115-163 (2008).
13. Kryczek, I. et al. Cutting edge: Th17 and regulatory T cell dynamics and the regulation by IL-2 in the tumour microenvironment. J. Immunol. 178, 6730-6733 (2007).
14. Kryczek, I. et al. Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumour environments. Blood 11 4, 1141-1149 (2009).
15. Muranski, P. et al. Tumour-specific Th17-polarized cells eradicate large established melanoma. Blood 11 2, 362-373 (2008).
16. + T cell trafficking and development by IFN-γ: mechanism and pathological relevance in psoriasis. J. Immunol. 181, 4733-4741 (2008).
17. Martin-Orozco, N. et al. T helper 17 cells promote cytotoxic T cell activation in tumour immunity. Immunity 31, 787-798 (2009).
18. Zou, W. et al. Stromal-derived factor-1 in human tumours recruits and alters the function of plasmacytoid precursor dendritic cells. Nature Med. 7, 1339-1346 (2001).
19. Kryczek, I. et al. CXCL12 and vascular endothelial growth factor synergistically induce neoangiogenesis in human ovarian cancers. Cancer Res. 65, 465-472 (2005).
20. Bell, D. et al. In breast carcinoma tissue, immature dendritic cells reside within the tumour, whereas mature dendritic cells are located in peritumoral areas. J. Exp. Med. 190, 1417-1426 (1999).
21. Acosta-Rodriguez, E. V. et al. Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells. Nature Immunol. 8, 639-646 (2007).
22. Annunziato, F. et al. Phenotypic and functional features of human Th17 cells. J. Exp. Med. 204, 1849-1861 (2007).
23. + T cells display enhanced anti-tumour immunity. Blood 11 4, 596-599 (2009).
24. +T cell responses. J. Exp. Med. 204, 1405-1416 (2007).
25. + T cells is reflected by their avidity, polyfunctionality, and clonal turnover. J. Exp. Med. 204, 2473-2485 (2007).
26. Kryczek, I. et al. Cutting edge: IFN-γ enables APC to promote memory Th17 and abate Th1 cell development. J. Immunol. 181, 5842-5846 (2008).
27. Kryczek, I. et al. B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J. Exp. Med. 203, 871-881 (2006).
28. + IL-17-producing T cells in ovarian cancer. Proc. Natl Acad. Sci. USA 105, 15505-15510 (2008).
29. H17 cells. Nature 454, 350-352 (2008).
30. H-17 cells requires transforming growth factor-β and induction of the nuclear receptor RORγt. Nature Immunol. 9, 641-649 (2008).
31. H-17 responses. Nature Immunol. 9, 650-657 (2008).
32. Wilson, N. J. et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nature Immunol. 8, 950-957 (2007).
33. Acosta-Rodriguez, E. V., Napolitani, G., Lanzavecchia, A. & Sallusto, F. Interleukins 1β and 6 but not transforming growth factor-β are essential for the differentiation of interleukin 17-producing human T helper cells. Nature Immunol. 8, 639-646 (2007).
34. Zou, W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nature Rev. Cancer 5, 263-274 (2005).
35. + T cell pool IL-1 subverts IL-2-mediated suppression. J. Immunol. 179, 1423-1426 (2007).
36. Chung, Y. et al. Critical regulation of early Th17 cell differentiation by interleukin-1 signalling. Immunity 30, 576-587 (2009).
37. Gulen, M. F. et al. The receptor SIGIRR suppresses Th17 cell proliferation via inhibition of the interleukin-1 receptor pathway and mTOR kinase activation. Immunity 32, 54-66 (2010).
38. Curiel, T. J. et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nature Med. 10, 942-949 (2004).
39. H17 and regulatory T cell differentiation mediated by retinoic acid. Science 317, 256-260 (2007).
40. H17 and regulatory T cells. Nature 441, 235-238 (2006).
41. Beriou, G. et al. IL-17-producing human peripheral regulatory T cells retain suppressive function. Blood 11 3, 4240-4249 (2009).
42. + regulatory T cells in humans. Proc. Natl Acad. Sci. USA 106, 4793-4798 (2009).
43. Kryczek, I., Grybos, M., Karabon, L., Klimczak, A. & Lange, A. IL-6 production in ovarian carcinoma is associated with histiotype and biological characteristics of the tumour and influences local immunity. Br. J. Cancer 82, 621-628 (2000).
44. Deaglio, S. et al. Adenosine generation catalysed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J. Exp. Med. 204, 1257-1265 (2007).
45. + Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood 11 0, 1225-1232 (2007).
46. Kao, J. Y. et al. Helicobacter pylori immune escape is mediated by dendritic cell-induced Treg skewing and Th17 suppression in mice. Gastroenterology 138, 1046-1054 (2010).
47. H17 responses in a Stat3-dependent manner. Science 326, 986-991 (2009).
48. + T cells. Curr. Opin. Immunol. 21, 200-208 (2009).
49. Lee, Y. K. et al. Late developmental plasticity in the T helper 17 lineage. Immunity 30, 92-107 (2009).
50. Yen, H. R. et al. Tc17 CD8 T cells: functional plasticity and subset diversity. J. Immunol. 183, 7161-7168 (2009).
51. Bending, D. et al. Highly purified Th17 cells from BDC2.5NOD mice convert into Th1-like cells in NOD/ SCID recipient mice. J. Clin. Invest. 11 9, 565-572 (2009).
52. Martin-Orozco, N., Chung, Y., Chang, S. H., Wang, Y. H. & Dong, C. Th17 cells promote pancreatic inflammation but only induce diabetes efficiently in lymphopenic hosts after conversion into Th1 cells. Eur. J. Immunol. 39, 216-224 (2009).
53. Nurieva, R., Yang, X. O., Chung, Y. & Dong, C. Cutting edge: in vitro generated Th17 cells maintain their cytokine expression program in normal but not lymphopenic hosts. J. Immunol. 182, 2565-2568 (2009).
54. Luger, D. et al. Either a Th17 or a Th1 effector response can drive autoimmunity: conditions of disease induction affect dominant effector category. J. Exp. Med. 205, 799-810 (2008).
55. O'Connor, W. Jr et al. A protective function for interleukin 17A in T cell-mediated intestinal inflammation. Nature Immunol. 10, 603-609 (2009).
56. Muranski, P. & Restifo, N. P. Does IL-17 promote tumour growth? Blood 11 4, 231-232 (2009).
57. Munn, D. H. Th17 cells in ovarian cancer. Blood 11 4, 1134-1135 (2009).
58. Bronte, V. Th17 and cancer: friends or foes? Blood 11 2, 214 (2008).
59. Kryczek, I., Wei, S., Szeliga, W., Vatan, L. & Zou, W. Endogenous IL-17 contributes to reduced tumour growth and metastasis. Blood 11 4, 357-359 (2009).
60. Hirahara, N. et al. Inoculation of human interleukin-17 gene-transfected Meth-A fibrosarcoma cells induces T cell-dependent tumour-specific immunity in mice. Oncology 61, 79-89 (2001).
61. Benchetrit, F. et al. Interleukin-17 inhibits tumour cell growth by means of a T-cell-dependent mechanism. Blood 99, 2114-2121 (2002).
62. Wei, S., Kryczek, I., Namm, J., Szeliga, W., Vatan, L., Chang, A. E. & Zou, W. Endogenous IL-17, tumour growth and metastasis. Blood (in the press).
63. + Tregs to TH17-like cells in tumour-draining lymph nodes. Blood 11 3, 6102-6111(2009).
64. Pellegrini, M. et al. Adjuvant IL-7 antagonizes multiple cellular and molecular inhibitory networks to enhance immunotherapies. Nature Med. 15, 528-536 (2009).
65. Kottke, T. et al. Induction of hsp70-mediated Th17 autoimmunity can be exploited as immunotherapy for metastatic prostate cancer. Cancer Res. 67, 11970-11979 (2007).
66. H17 and Treg skewing. Clin. Cancer Res. 14, 3254-3261 (2008).
67. von Euw, E. et al. CTLA4 blockade increases Th17 cells in patients with metastatic melanoma. J. Transl. Med. 7, 35 (2009).
68. Galon, J. et al. Type, density, and location of immune cells within human colorectal tumours predict clinical outcome. Science 313, 1960-1964 (2006).
69. Zhang, L. et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 348, 203-213 (2003).
70. +/regulatory T cell ratio are associated with favourable prognosis in ovarian cancer. Proc. Natl Acad. Sci. USA 102, 18538-18543 (2005).
71. Tartour, E. et al. Interleukin 17, a T-cell-derived cytokine, promotes tumorigenicity of human cervical tumours in nude mice. Cancer Res. 59, 3698-3704 (1999).
72. Numasaki, M. et al. IL-17 enhances the net angiogenic activity and in vivo growth of human non-small cell lung cancer in SCID mice through promoting CXCR-2-dependent angiogenesis. J. Immunol. 175, 6177-6189 (2005).
73. Numasaki, M. et al. Interleukin-17 promotes angiogenesis and tumour growth. Blood 101, 2620-2627 (2003).
74. Wu, S. et al. A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nature Med. 15, 1016-1022 (2009).
75. Wang, L. et al. IL-17 can promote tumour growth through an IL-6-Stat3 signalling pathway. J. Exp. Med. 206, 1457-1464 (2009).
76. Kawakami, Y. et al. Inhibition of NK cell activity by IL-17 allows vaccinia virus to induce severe skin lesions in a mouse model of eczema vaccinatum. J. Exp. Med. 206, 1219-1225 (2009).
77. Langowski, J. L. et al. IL-23 promotes tumour incidence and growth. Nature 442, 461-465 (2006).
78. Hu, J. et al. Induction of potent antitumour immunity by intratumoral injection of interleukin 23-transduced dendritic cells. Cancer Res. 66, 8887-8896 (2006).
79. Yuan, X., Hu, J., Belladonna, M. L., Black, K. L. & Yu, J. S. Interleukin-23-expressing bone marrow-derived neural stem-like cells exhibit antitumour activity against intracranial glioma. Cancer Res. 66, 2630-2638 (2006).
80. Overwijk, W. W. et al. Immunological and antitumour effects of IL-23 as a cancer vaccine adjuvant. J. Immunol. 176, 5213-5222 (2006).
81. Oniki, S. et al. Interleukin-23 and interleukin-27 exert quite different antitumour and vaccine effects on poorly immunogenic melanoma. Cancer Res. 66, 6395-6404 (2006).
82. Kaiga, T. et al. Systemic administration of IL-23 induces potent antitumour immunity primarily mediated through Th1-type response in association with the endogenously expressed IL-12. J. Immunol. 178, 7571-7580 (2007).
83. Gattinoni, L., Powell, D. J. Jr, Rosenberg, S. A. & Restifo, N. P. Adoptive immunotherapy for cancer: building on success. Nature Rev. Immunol. 6, 383-393 (2006).
84. + T cells for effective immunotherapy. Curr. Opin. Immunol. 18, 363-370 (2006).
85. + T helper cells and hindered by naturally occurring T regulatory cells. J. Immunol. 174, 2591-2601 (2005).
86. Zou, W. Regulatory T cells, tumour immunity and immunotherapy. Nature Rev. Immunol. 6, 295-307 (2006).
87. Mellor, A. L. & Munn, D. H. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nature Rev. Immunol. 4, 762-774 (2004).
88. Gabrilovich, D. Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nature Rev. Immunol. 4, 941-952 (2004).
89. Bronte, V. & Zanovello, P. Regulation of immune responses by l-arginine metabolism. Nature Rev. Immunol. 5, 641-654 (2005).
90. Zitvogel, L., Tesniere, A. & Kroemer, G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nature Rev. Immunol. 6, 715-727 (2006).
91. + T cells against NY-ESO-1. N. Engl. J. Med. 358, 2698-2703 (2008).
92. Miossec, P., Korn, T. & Kuchroo, V. K. Interleukin-17 and type 17 helper T cells. N. Engl. J. Med. 361, 888-898 (2009).
93. Rosenberg, S. A., Restifo, N. P., Yang, J. C., Morgan, R. A. & Dudley, M. E. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nature Rev. Cancer 8, 299-308 (2008).
94. H17 cells in B-cell non-Hodgkin's lymphoma. Cancer Res. 69, 5522-5530 (2009).
95. + T-cell axis in patients with breast cancer. Br. J. Cancer 100, 1061-1067 (2009).
96. Zhang, B. et al. The prevalence of Th17 cells in patients with gastric cancer. Biochem. Biophys. Res. Commun. 374, 533-537 (2008).
97. Zhang, J. P. et al. Increased intratumoral IL-17-producing cells correlate with poor survival in hepatocellular carcinoma patients. J. Hepatol 50, 980-989 (2009).
98. Wang, W. et al. Effects of high-dose IFNα2b on regional lymph node metastases of human melanoma: modulation of STAT5, FOXP3, and IL-17. Clin. Cancer Res. 14, 8314-8320 (2008).
99. Dhodapkar, K. M. et al. Dendritic cells mediate the induction of polyfunctional human IL17-producing cells (Th17-1 cells) enriched in the bone marrow of patients with myeloma. Blood 11 2, 2878-2885 (2008).
100. Charles, K. A. et al. The tumour-promoting actions of TNF-α involve TNFR1 and IL-17 in ovarian cancer in mice and humans. J. Clin. Invest. 11 9, 3011-3023 (2009).
101. + T-cells, but not Tregs, correlates with clinical response to whole-cell vaccination in prostate cancer patients. Int. J. Cancer 125, 1372-1379 (2009).
102. Inozume, T., Hanada, K., Wang, Q. J. & Yang, J. C. IL-17 secreted by tumour reactive T cells induces IL-8 release by human renal cancer cells. J. Immunother. 32, 109-117 (2009).
103. + regulatory T cells in small cell lung cancer reflects disease stage. Clin. Cancer Res. 14, 6770-6779 (2008).
104. Coury, F. et al. Langerhans cell histiocytosis reveals a new IL-17A-dependent pathway of dendritic cell fusion. Nature Med. 14, 81-87 (2008).
105. H-17 cell mediated pathology. Nature Immunol. 8, 1390-1397 (2007).
106. Fitzgerald, D. C. et al. Suppression of autoimmune inflammation of central nervous system by interleukin 10 secreted by interleukin 27-stimulated T cells. Nature Immunol. 8, 1372-1379 (2007).
107. Stumhofer, J. S. et al. Interleukins 27 and 6 induce STAT3-mediated T cell production of interleukin 10. Nature Immunol. 8, 1363-1371 (2007).